Results from a post-hoc analysis of the phase 3 TROPION-Lung01 trial (NCT04656652) shared at the International Association for the Study of Lung Cance...

In this episode, CancerNetwork® spoke with Joseph S. Wallins, MD, MPH, cardiology fellow at Weill Cornell Medicine, about a review of cardiotoxicities...

Bispecific antibodies in multiple myeloma are currently approved for patients who have undergone at least 4 prior lines of therapy, but their use is r...

Video content above is prompted by the following: Pembrolizumab plus axitinib emerged as the first FDA-approved IO-TKI combination for first-line clea...

Video content above is prompted by the following: CheckMate 9ER established nivolumab plus cabozantinib as a potent immunotherapy-tyrosine kinase inhi...

In an interview with CancerNetwork® on nutrition in cancer treatment, Denise B. Reynolds, registered dietitian at Atrium Health Levine Cancer, discuss...

Trastuzumab pamirtecan (BNT323/DB-1303) displayed enhanced progression-free survival (PFS) vs ado-trastuzumab emtansine (T-DM1; Kadcyla) in patients w...

According to Sundar Jagannath, MBBS, the cure for multiple myeloma has been observed in the 12 patients who participated in the phase 1b/2 CARTITUDE-1...

According to Denise B. Reynolds, RD, registered dietitian at Atrium Health Levine Cancer, smaller and more frequent meals may help mitigate the occurr...

The latest screening algorithm for the Shield™ blood test (Shield V2) demonstrated positive sensitivity and specificity outcomes in the detection of c...